29 3 2 0 0 8 6 ( ) J ournal of Xiπan J iaot ong U niversity (Medical Sciences) V ol. 29 No. 3 J un. 2008 1, 2, 3, 4, 2 (1., 300162 ;2., 710061 ;3., 300162 ; 4., 830000) : M TT ; H E ; Western Blot2 ting Bcl22 ; p2sta T3 2 3 STA T3, STA T3, : ; ; :R967 :A :167128259 (2008) 0320340206 Anti2leukemia effect of resveratrol of Polygonum cuspidatum exerts and possible molecular mechanism Li Tan 1, Fan Guixiang 2, Wang Wei 3, Li Tong 4, Yuan Yukang 2 (1. Depart ment of Immunology, Medical College of t he Chinese Peopleπs Armed Police Force, Tianjin 300162 ; 2. Depart ment of Immunology and Pat hogenic Biology, Medical School of Xiπan Jiaotong U niversity, Xiπan 710061 ; 3. Department of Nep hrology, t he Affiliated Hospital of Medical College of t he Chinese Peopleπs Armed Police Force, Tianjin 300162 ; 4. Department of Ultrasonography, Xinjiang Armed Police General Hospital, Urumqi 830000, China) ABSTRACT : Objective To explore t he anti2leukemia eff ects of resverat rol on t hree leukemia cell lines Hu T278, J urkat and L 1210 in vivo. Methods M TT colorimet ry was used t o measure t he tumor cell growt h rep ression rate. The level of Bcl22 was measured by Wester n blotting. The cell cycle of cells was analyzed by flow cyt omet ry. The exp ression of p2s TA T3 was determined by immunohist ochemistry. Results Our findings indicated t hat resverat rol could inhibit p rolif eration, induce ap op t osis, and influence cell cycle of Hu T278, J urkat and L 1210 cells in a dose2 and time2dependent manner and reduce t he exp ression of p2s TA T3 in vitro. Conclusion Resverat rol might have a chemot herapeutic p ote ntial f or leukemia of various sources and reduce t he exp ression of p2s TA T3 w hich p rovides experiment evidence f or its application in clinical t reat ment of leukemia. KEY WORDS : resverat rol ; ap op t osis ; leukemia,,,,,, [1],,, :2007210216 :2007211212 : (19782), ( ),,,. E2mail : litan2002 @eyou. com, (trans2resveratrol), [2],,, 3,,
3,,,. 341 1 1. 1 ( 98. 36 %) ; M T T Sigma ; RPMI 1640 ( FCS) Gibco ; ( ) Bcl22 Labvision ; ( ) p2 STA T3 Santa Cruz ; Annexin V2FITC ; (L1210) ; T ( Hu T278) T (J ur2 kat, Clone E621) 1. 2 37 5 % ( ) CO2, 10 %( ) 1640,800 r/ min 5 min, 1 3 1 4, 1640 > 95 %, Nikon TMS2F 1. 3 2 ( HE) 0. 78 1. 56 3. 13 6. 25 12. 50 25 50 100 mol/ L 12 24 48 h,,he 1. 4 M T T RPMI 1640 5 000 / ml, [3 ], 3 T3 1. 5 24 h, 0. 5 %( ) RPMI 1640 12 h [4 ], 1 10 5 / ml 3 ml,,5 %( ) CO2,37, 6 h PI FACSCalibur 1. 6 1 10 5 / ml,, 5 % ( ) CO2, 37, 12 24 48 h FITC Annexin2 V PI FACS2 can 1. 7 Western Bcl22, 2 mg/ L SDS2PAGE, 1. 5-2 h Bcl22 ( TBST 1 200 ),HRP2 ( TBST 1 5 000 ),ECL, 2actin 1. 8 SP HuT278 J urkat L1210 p2stat 3 p2sta T3 1 100,DAB, 0. 01 mol/ L PBS, : ( - ) < 10 % ; ( + ) 10-40 % ; ( 6 ) 40-70 % ; ( 7 ) > 70 % 1. 9 SPSS13. 0 (one way ANOVA), ; Bonferroni t P < 0. 05 2 2. 1 Hu T278 J urkat L1210 0. 78 1. 56 3. 13 6. 25 12. 50 25 50 100 mol/ L Hu T278 J urkat L1210 12 24 48 h,,, ( 1) 2. 2 H E,,,,,,,,,,,,, ( 2) 2. 3,3 Hu T278 J ur2 kat L1210, - ( 3A - 3C), L1210, 66. 17 % ; Hu T278 J urkat 62. 24 % 45. 98 % 3, ( 3D), 3 T3 ( P < 0. 01), L1210 Hu T278,L1210 J urkat 12 h ( P < 0. 05), ; J urkat Hu T278, 48 h ( P < 0. 01)
342 ( ) 29
3,,,. 343 2. 4, G0 / G1 34. 93 % 30. 12 %, S 41. 14 % 49. 17 % ( Hu T278) ;J urkat ;L1210 S : 59. 02 % 65. 57 %, S ( 4) 4 PI ( 6 h) Fig. 4 Resveratro2induced cell cycle perturbations and apoptosis in HuT278, J urkat and L1210 cells cultured for 6 h. Cells stained with PI A, C, E: control cells incubated without resveratrol ; B, D, F : HuT 78, Jurkat and L1210 cells treated with 50 mol/ L resveratrol, respectively 2. 5 50 mol/ L 12 h, 25 %L1210, 48 h, ( 5) ( 6), 100 mol/ L 12 h, HuT278 (84. 33 %) ;J urkat L1210 41. 99 % 50. 94 %,, HuT278 L1210 J urkat 2. 6 Bcl22 3 Bcl22, Hu T278 J urkat L1210 Bcl22, ( 7) 5 50 mol/ L L1210 Fig. 5 The morphology of apoptotic cells treated with 50 mol/ L resveratrol ( 20) A : 12 h ; B : 48 h 6 100 mol/ L 12 h Fig. 6 The apoptotsis of different cells treated with 100 mol/ L resveratrol for 12 h by flow cytometric analysis A : Hu T278 cells ; B : J urkat cells ; C : L1210 cells
344 ( ) 29 2. 7 Hu T278 J urkat L1210 p2stat 3 p2stat 3, > 70 %,p2stat 3 ( P < 0. 05, 8) 7 48 h, Hu T278 J urkat L1210 Bcl22 Fig. 7 The relative expression level of Bcl22 in Hu T278, J urkat and L1210 cells treated with different doses of res2 veratrol for 48 h 3, L1210 Hu T278 J urkat, 3, L1210 Hu T278 J urkat, [5 ],,, [6 ], 3 Western Blot, Hu T278 J urkat L1210 Bcl22, 8 Hu T278 J urkat L1210 p2sta T3 Fig. 8 The expression of p2sta T3 in Hu T278, J urkat and L1210 cells A : p2sta T3 in Hu T278 ; B : p2sta T3 in Hu T278 treated wit h 100 mol/ L resveratrol for 24 h ; C : p2sta T3 in J urkat ; D : p2sta T3 in J urkat treated wit h 100 mol/ L resveratrol for 24 h ; E : p2sta T3 in L1210 ; F : p2sta T3 in L1210 treated wit h 100 mol/ L resveratrol for 24 h Bcl22, Bcl22,Bcl22 Bcl22, [728 ], Bcl22,, J A K/ STA T ( signal transducers and activators of transcription, ) [9210 ] STA T DNA,
3,,,. 345,,,, STA T3, DNA, ( Bcl22),,,3 STA T3, p2sta T3 STA T3, Bcl22,,, Hu T278 L1210 S,J urkat DNA, DNA, S [11 ] DNA, 3, [12 ],,,,,,,, p532 / p532 N F2 B [13214 ],,, Bcl22, [15216 ],, : [ 1 ],. [ M ]. :, 1999 :72287. [ 2 ],,,. [J ]., 2007, 29 (4) :5162521. [ 3 ]. [ M ]. :, 1997 :8182819. [ 4 ] Ishida N, Hara T, Kamura T, et al. Phosp horylation of p27 Kip1 on serine 10 is required f or its binding to CRM1 and nuclear exp ort [J ]. J Biol Chem, 2002, 277 (17) :14355214358. [ 5 ]L a ncon A, Del ma D, Osma n H, et al. Huma n hepatic cell up2 take of resveratrol : involvement of both passive diff usion and carrier2mediated process [ J ]. Biochem Biop hys Res Commun, 2004, 316 (4) :113221137. [ 6 ] Reddy L, Odhav B, B hoola KD. Natural p roducts f or ca ncer p revention : a global perspective [J ]. Phar macol Ther, 2003, 99 (1) :1213. [ 7 ] Thomadaki H, Scorilas A. BCL 2 f a mily of apoptosis2related genes : f unctions and clinical implications in cancer [ J ]. Rev Clin L ab Sci, 2006, 43 (1) :1267. Crit [ 8 ] Haf ez M, Al2Tonbary Y, El2Bayoumi MA, et al. Markers of apoptosis and p rolif eration related gene products as predictors of treat ment outcome in childhood acute lymp hoblastic leukemia [J ]. He matology, 2007, 12 (3) :2092218. [ 9 ]Shide K, Shimoda K, Ka mezaki K, et al. Tyk2 mutation ho2 mologous to V617F J ak2 is not f ound in essential thrombo2 cythaemia, although it induces constitutive signaling and growth f act or independence [J ]. L euk Res, 2007, 31 (8) :107721084. [ 10 ] Poincloux R, Cougoule C, Daubon T, et al. Tyrosine2p hosp ho2 rylated S TA T5 accumulates on podosomes in Hck2transf or med fibroblasts and chronic myeloid leukemia cells [J ]. J Cell Physi2 ol, 2007, 213 (1) :2122220. [ 11 ] Ragione FD, Cucciolla V, Borriello A, et al. Resveratrol ar2 rests the cell division cycle at S/ G2 p hase transition [J ]. Bio2 che m Biop hys Res Commun, 1998, 250 (1) :53258. [ 12 ] Kotha A, Sekhara m M, Cilenti L, et al. Resveratrol inhibits Src and Stat3 signaling and induces the ap optosis of malignant cells containing activated Stat3 p rotein [ J ]. Mol Cancer Ther, 2006, 5 (3) :6212629. [ 13 ] Aggarwal BB, Shishodi S. Molecular targets of dietary agents f or p revention and t herapy of ca ncer [J ]. Bioche m p har macol, 2006, 71 (10) :139721421. [ 14 ]Bode AM, Dong Z. Targeting signal transduction pathways by chemopreventive agents[j ]. Mutat Res/ Funda m Mol Mech Mu2 tagen, 2004, 555 (122) :33251. [ 15 ],,,. [J ]., 2004, 24 (2) :21222. [ 16 ] Maccarrone M, L orenzon T, Guerrieri P, et al. Resveratrol prevents ap optosis in K562 cells by inhibiting lip oxygenase and cyclooxygenase activity [ J ]. Eur J Biochem, 1999, 265 ( 1 ) : 27234. ( )